DNA methylation epigenotypes in breast cancer molecular subtypes by Bediaga, Naiara G et al.
RESEARCH ARTICLE Open Access







3, Irune Ruiz Diaz
4,
Ricardo Rezola
5, María Jesus Alberdi
5, Joaquín Dopazo
6, David Montaner
6, Mertxe de Renobales
7,
Agustín F Fernández
8, John K Field
9, Mario F Fraga
10, Triantafillos Liloglou
9, Marian M de Pancorbo
1*
Abstract
Introduction: Identification of gene expression-based breast cancer subtypes is considered a critical means of
prognostication. Genetic mutations along with epigenetic alterations contribute to gene-expression changes
occurring in breast cancer. So far, these epigenetic contributions to sporadic breast cancer subtypes have not been
well characterized, and only a limited understanding exists of the epigenetic mechanisms affected in those
particular breast cancer subtypes. The present study was undertaken to dissect the breast cancer methylome and
to deliver specific epigenotypes associated with particular breast cancer subtypes.
Methods: By using a microarray approach, we analyzed DNA methylation in regulatory regions of 806 cancer-
related genes in 28 breast cancer paired samples. We subsequently performed substantial technical and biologic
validation by pyrosequencing, investigating the top qualifying 19 CpG regions in independent cohorts
encompassing 47 basal-like, 44 ERBB2+ overexpressing, 48 luminal A, and 48 luminal B paired breast cancer/
adjacent tissues. With the all-subset selection method, we identified the most subtype-predictive methylation
profiles in multivariable logistic regression analysis.
Results: The approach efficiently recognized 15 individual CpG loci differentially methylated in breast cancer tumor
subtypes. We further identified novel subtype-specific epigenotypes that clearly demonstrate the differences in the
methylation profiles of basal-like and human epidermal growth factor 2 (HER2)-overexpressing tumors.
Conclusions: Our results provide evidence that well-defined DNA methylation profiles enable breast cancer
subtype prediction and support the utilization of this biomarker for prognostication and therapeutic stratification of
patients with breast cancer.
Introduction
Breast cancer is a heterogeneous disease, both biologi-
cally and clinically. The molecular background behind
breast cancer progression is not well understood, but is
associated with the accumulation of genetic aberrations,
leading to widespread gene-expression changes in breast
tumor cells. Consistent with this is the presence of at
least four major breast cancer subtypes with distinct
expression patterns and clinical outcomes. These sub-
types are termed basal-like, ERBB2+, luminal B, and
luminal A [1,2]. Basal-like and ERBB2+ subtypes are
hormone-receptor negative and have poor prognoses. In
contrast, luminal breast cancers are characterized by the
expression of ER-associated genes, with luminal B
tumors having poorer outcomes than luminal A tumors.
Although this gene expression-based approach has pro-
ven to add significant prognostic and predictive value to
pathologic staging, histologic grade, and standard clini-
cal molecular markers [3], the high cost of expression
profiling and the molecular instability of the mRNA
transcripts has limited its incorporation into clinical set-
tings, and therefore, expression-based breast cancer clas-
sification has not become a standardized method in
the general practice [4]. Thus, although breast cancer
stratification by gene expression is still considered the
gold standard, an urgent need exists for well-defined
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clinical diagnostics.
Epigenetic alterations such as aberrations in DNA
methylation, microRNA patterns, and post-translational
modifications of histones are common molecular
abnormalities in cancer [5]. Furthermore, many studies
suggest that epigenetic changes are involved in the ear-
liest phases of tumorigenesis, and that they may predis-
pose stem/progenitor cells to subsequent genetic and
epigenetic changes involved in tumor promotion [6].
Cancer-related disruption of the DNA methylome
involves global genomic hypomethylation and regional
hypermethylation of cytosine-phosphate-guanine (CpG)
islands. The first can lead to chromosomal instability
[7], whereas the second is frequently associated with
promoters of tumor-suppressor genes, resulting in their
transcriptional silencing. Both such alterations have
been frequently observed in breast cancer [8-19].
Analogous to transcriptomic profiling, DNA methyla-
tion profiling is considered to allow the molecular classi-
fication of human malignancies and monitoring cancer
progression based on a tumor-specific methylation sig-
nature [20]. At the same time, it facilitates biomarker
discovery for the clinical implementation of this process.
Previous epigenetic analyses have identified aberrant
DNA methylation signatures associated with molecular
subtypes of breast cancer through hormone-receptor
and human epidermal growth factor 2 (HER2) status
[21-23]; however, very limited information is available
on global methylation changes associated with each
molecular subtype, as previous studies focused on indi-
vidual candidate tumor-suppressor genes by using locus-
specific methods. Here we have applied an array-based
method [24] for comprehensive DNA methylation pro-
filing to identify differentially methylated genes in breast
cancer molecular subtypes. This approach efficiently
recognized 15 differentially DNA-methylated loci, which
were further validated through pyrosequencing in an
independent cohort encompassing 47 basal-like, 44
ERBB2+ overexpressing, 48 luminal A, and 48 luminal B
paired breast cancer/adjacent tissues. Our results pro-
vide strong evidence for the existence of tumor subtype-
specific aberrant methylation profiles, which might be
inducers of some transcriptional changes taking place in
breast cancer molecular subtypes.
Materials and methods
Patients and tumor characteristics
Samples and associated clinicopathologic data were
obtained from the Anatomy Pathological Services of the
Txagorritxu Hospital, Oncologic Institute of Donostia, and
Donostia Hospital (Basque Country). Samples of breast
tumor and corresponding adjacent normal-appearing
tissue (located at least 2 cm away from the site at
which the tumor was sampled) were collected from 215
patients diagnosed with a ductal infiltrative breast
carcinoma.
DNA-methylation measurements were performed on
DNA isolated from paraffin-embedded primary breast
cancer. All breast specimens were reviewed by experi-
enced pathologists. The inclusion criteria were the avail-
ability of the paraffin-embedded tissue, tumor size
between 1 and 3 cm, histologic grade between 1 and 3,
and estrogen receptor (ER)-, progesterone receptor
(PR)-, HER2-, CK5/6+, or CK14+, or EFGR+ for the
basal-like tumors, ER+, PR±, and HER2+ for the Lumi-
n a lB ,E R - ,P R - ,a n dH E R 2 +f o rt h eE R B B 2 +t u m o r
group, and ER+, PR+, and HER2- for the Luminal A.
Additional data such as Ki-67 status, p53 mutation, and
nodal involvement were also registered. Ethical approval
for the study was obtained from the corresponding
Ethics Committees of the Institutions involved.
Macrodissection, DNA extraction, and bisulfite
modification
To minimize contamination in the methylation analysis,
we isolated breast cancer cells and paired normal breast
epithelial cells from tissues by manual macrodissection.
In brief, 10-μm sections were cut from each archival for-
malin-fixed paraffin-embedded (FFPE) tissue block. For
each pair of tissues, the presence of tumor cells in
malignant tissues and the absence of cancer cells in nor-
mal tissues were confirmed by histopathologic
examination.
A total of 500 μl of buffer TE pH 9 was added to each
sample and heated at 100°C for 20 minutes by using a
water bath. After heating, a cooling step of 5 minutes
was allowed before adding 20 μl of proteinase K. Sam-
ples were incubated at 56°C overnight until all the tissue
fragments were completely dissolved. Subsequent extrac-
tion and purification procedures were performed after
the next steps: addition of 500 μl phenol/chloroform/
isopropanol alcohol (25:24:1) to the digested tissue, fol-
lowed by mixing for 10 minutes and centrifugation at
12,000 rpm for 10 minutes. The supernatant fluid was
removed to an autoclaved microtube, and one volume
of chloroform/isopropanol alcohol (25:1) was added,
mixed by vortexing, and centrifuged at 12,000 rpm for
10 minutes. The upper aqueous supernatant was puri-
fied by using a DNA purification kit, following the man-
ufacturer’s instructions (Qiagen, Valencia, Spain), and
the final yield of DNA was dissolved in 50 μlo fb u f f e r
TE. Sodium bisulfite modification of 1.5 μgD N Aw a s
done with the EZ DNA methylation kit (Zymo Research,
Orange, CA, USA) by following the manufacturer’s
protocol.
Bediaga et al. Breast Cancer Research 2010, 12:R77
http://breast-cancer-research.com/content/12/5/R77
Page 2 of 12Marker discovery study
Illumina GoldenGate Methylation Cancer Panel 1
The Illumina GoldenGate Methylation Cancer Panel was
used to analyze 550 ng of starting bisulfite-modified
genomic DNA. Methylation was represented as a con-
tinuous value from 0 (completely unmethylated) to 1
(completely methylated). This value is calculated by sub-
tracting background hybridization levels obtained from
negative control probes on the array and calculating the
ratio of the fluorescent signal from the methylated allele
(M) to the sum of the fluorescent signals from both
unmethylated (U) and methylated alleles (|U|+|M|+100).
Differential methylation analysis
Microarray data were analyzed to identify the most sig-
nificant tumor subtype-specific changes relative to the
adjacent tissue. Differential methylation was assessed by
comparing the mean methylation level (b-value) of sam-
ples with the mean b-value of the corresponding adja-
cent tissue by using BeadStudio (San Diego, CA, USA)
and Qlucore Omics Explorer 2.0 (Qlucore AB, Lund,
Sweden) software. Selection of the most significantly dif-
ferentially methylated loci in each tumor subtype was
based on (a) Δb value difference of at least 0.20 between
the tumors and reference group; (b) an FRD-corrected
P value cut off of P < 0.001, as determined by a two-
tailed t test [25]; and (c) a P value < 0.05 when compar-
ing mean methylation values among the studied tumor
subtypes by using analysis of variance (ANOVA) test
with Benjamini-Hochberg FDR multiple testing correc-
tion. The methylation data have been deposited in
NCBI’s Gene Expression Omnibus (GEO) [26] and are
accessible through GEO Series accession number [GEO:
GSE22135].
Validation of the data by pyrosequencing
PCR and pyrosequencing reactions
Selected markers from microarray data analysis were
further validated in a larger sample size by bisulfite/pyr-
osequencing. Additionally, four candidates from the lit-
erature were included: LINE-1,t om e a s u r et h eg l o b a l
hypomethylation of the tumors [27], and Let-7a, Mir-
10a,a n dMir-93 microRNAs, because they have been
reported to be differently expressed in breast cancer
molecular subtypes [28], and their expression might be
regulated by methylation in some tumor subtypes, and
thus provide new potential subtype-specific biomarkers.
For the methylation analysis, 1.5 μg of genomic DNA
was treated with sodium bisulfite, by using the EZ DNA
methylation Kit (Zymo Research, Orange, CA, USA)
according to the manufacturer’s protocol. All primers
were designed by using the Assay Design Software (Bio-
tage, Uppsala, Sweden) and synthesized by MWG
(Ebersberg, Germany). PCR amplifications were per-
formed by using Qiagen HotStarTaq Master Mix Kit
(Qiagen, Valencia, Spain), 7.5 μM biotinylated primer,
15 μM nonbiotinylated primer, and 2 μlo fb i s u l f i t e -
treated DNA (60 ng). PCR primer sequences, PCR con-
ditions, and sequencing primer sequences are given in
Table S1 in Additional file 1. The quality and quantity
of the PCR product was confirmed by agarose gel (2%)
electrophoresis before the cleanup and pyrosequencing
analysis. Pyrosequencing was carried out by using the
SQA kit (Biotage, Uppsala, Sweden) on a PSQ 96MA
Pyrosequencer (Biotage), and the methylation index was
calculated by using the Pyro Q-CpG software (Biotage).
Validation data analysis
Methylation status in tumor versus adjacent tissue
Methylation status was assessed at the studied markers,
as previously described by Feng et al. [21]. Taking
advantage of paired normal/tumor samples, normal tis-
sues’ value was considered as the reference. If using the
pooled normal samples’ mean plus twice the standard
deviation as a cut-off point (minimum, 10%), we esti-
mated the probability of the methylation level for a nor-
mal-appearing tissue being lower than the cut-off point
is <96%. Thus, it is reasonable to assume that samples
with a methylation value larger than the cut-off point
are likely to be abnormal (or positive). A paired t test
was used to determine whether a statistically significant
change was present in the methylation of the markers
examined between the tumors and adjacent tissues.
Additionally, to allow the assessment of the observed
methylation at multiple promoters as a continuous vari-
able, Z-score analysis was used [29,30]. A Z score for
each gene was calculated by using the given formula:
Mean of CpG methylation density of the assessed pro-
moter for each sample - Mean of methylation density
for the tumor panel)/SD of methylation density.
A mean Z score was calculated by integrating the pro-
moter-specific Z scores and used as a simple score char-
acterizing mean methylation density. In this analysis, a
Z score >0 means methylation greater than the popula-
tion mean.
Comparison between methylation status, breast can-
cer molecular subtypes, and clinicopathologic charac-
teristic A one-sample Kolmogorov-Smirnov test was used
to evaluate fitness to normal distribution of continuous
parameters. Differences in promoter methylation among
tumor subtypes were analyzed with ANOVA or Kruskal-
Wallis tests as appropriate. The Wilcoxon signed-rank test
was used to compare methylation in paired samples. If dif-
ferences between two independent groups or clinicopatho-
logic characteristics had to be considered, a parametric
test (Student t test) or nonparametric test (Mann-Whitney
U test) was used. Comparisons of categoric variables were
made by using Fisher’s Exact and Pearson’s c
2 tests. All
reported P values are two-tailed and considered statisti-
cally significant if P < 0.05.
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(MLR) analysis was performed on those biomarkers
showing significance in univariate analysis to identify
potential biomarker panels capable of discriminating
breast cancer subtypes with the best sensitivity and spe-
cificity. Models including all possible combinations were
constructed and tested by Mallows’ Cp selection criter-
ion. The false discovery rate (FDR) of classifying breast
cancer subtypes was determined in the best models, and
we selected those significant at the FDR <0.2 level.
Supervised hierarchic clustering based on genes selected
in the models was performed by using an ANOVA test
(Benjamini-Hochberg FDR multiple testing corrected [25])
to confirm results obtained by MLR (Qlucore Omics
Explorer 2.0; Qlucore AB, Lund, Sweden). DNA methyla-
tion profiles were standardized to have a mean of zero and
a standard deviation of 1, and clustering was performed by
using the euclidean method and average linkage.
Ethical considerations
The present study involved analysis of DNA from archi-
val tissue with no subject intervention. No identities
were linked to subject records. This study was approved
by the Txagorritxu Hospital Review Board under the
category of exempt status, and no consent form was
required from the participants.
Results
Breast cancer subtypes display distinct clinicopathologic
characteristics
Patient characteristics are presented in Table 1. Basal-
like and ERBB2+ subtypes were more aggressive tumors
than luminal A and B ones, as indicated by their histolo-
gic and Ki-67 grades (P < 0.01), but the basal-like sub-
type showed less nodal involvement when compared
with other subtypes (P < 0.01). Additionally, p53 muta-
tion was significantly less frequent in the luminal A sub-
group (P < 0.05).
Array-based DNA methylation-profiling approach
identifies some breast cancer subtype-specific
methylation changes
DNA methylation-profiling analysis at 1,505 CpG loci was
performed in 30 paired breast cancer/adjacent tissues
representing the four major breast cancer subtypes. Two
of the tumor samples were eliminated from further analy-
sis secondary to their low methylation levels. The final
cohort consisted of 60 samples: 28 paired breast cancer/
adjacent tissues and four samples from the peritumoral
region. Extensive DNA methylation changes between
tumor and adjacent tissues were revealed after supervised
clustering of the samples (Figure 1; Table S2 in Additional
file 2). To identify CpGs with highly significant tumor
subtype-specific changes, stringent cut-offs (P < 0.001 and
Δb >0.20) were set for methylation-level changes relative
to controls for each tumor subtype. Distinct CpG loci
groups were identified, showing differential methylation
profiles in tumor subtypes. We focused in those genes that
were significantly differently methylated in the basal-like
tumor subtype (HOXA9, SOX1, VAMP8, and TNFRS10D)
and those that were significantly hypermethylated in the
luminal B tumors (NPY, RASSF1, HS3ST2, DBC1, FGF2,
CD40. SPARC, JAK3, SOX17, PRKCDBP,a n dTAL1).
Additionally, we compared mean methylation values
among the studied tumor subtypes by using ANOVA and
observed that NPY, PRKCDBP,a n dRASSF1 showed lower
methylation levels in the basal-like tumor subgroup when
compared with other subtypes, and that DBC1, HS3ST2,
FGF2,a n dCD40 displayed higher hypermethylation levels
in the luminal B subtype than in the other subgroups.
The microarray was technically validated by means of
pyrosequencing. Comparison of quantitative methylation
values at 5 CpG loci by both GoldenGate array and pyr-
osequencing in 20 samples confirmed the accuracy of
the array-based measurements (mean r
2 = 0.75; range,
0.56 to 0.91; Table S3 in Additional file 3).
Validation of differential methylation events in a large
panel of breast cancer tissue samples
For the validation study, pyrosequencing assays for 19
CpG loci were conducted in an independent cohort of
187 normal/breast cancer paired samples encompass-
ing 47 basal-like, 44 ERBB2+, 48 luminal A, and 48
luminal B samples. Differential methylation between
tumor and adjacent tissue was confirmed in the valida-
tion panel (Figure 2). Among the loci displaying >95%
specificity (that is, very low DNA methylation fre-
quency in normal tissue), the frequency of hyper-
methylation in tumor tissue ranged from 28% (DBC1,
deleted in bladder cancer 1) to 75% (JAK3,J a n u s
kinase 3), (see Table S4 in Additional file 4). Besides,
VAMP8 (vesicle-associated membrane protein 8) was
hypomethylated in 82% of the tumors, and LINE-1,t h e
global methylation marker, was highly methylated in
all normal tissues (mean = 68% ± 1.9%), whereas a sta-
tistically significant decrease was observed in tumors
(mean = 63% ± 5.4%; P <0 . 0 0 1 ) .
Further to define those CpG loci differentially methy-
lated in breast cancer subtypes, data were filtered on
significance of differences by using the Bonferroni-
corrected ANOVA test (P < 0.05). We found that 15 of
the 19 genes involved displayed different methylation
profiles in analyzed breast tumor subtypes (Table 2).
LINE-1, HOXA9, TAL1,a n dSPARC were excluded, as
they showed no significant difference. During the valida-
tion study, we confirmed that promoter methylation of
NPY, RASSF1, TNFRS10D, PRKCDBP, Let-7a,a n d
VAMP8 genes was lower in the basal-like subtype when
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and ERBB2+). SOX1 and SOX17 showed different
methylation levels between luminal B and luminal A
tumors. We also observed that HS3ST2, DBC1, FGF2,
CD40, JAK3, Mir-93,a n dMir-10a markers displayed
higher methylation levels in luminal B and ERBB2+ sub-
types than in the basal-like and the luminal A tumors.
Consequently, the validation study confirmed that these
markers were suitable for development of tumor-sub-
type methylation profiles.
One of the most interesting aspects of the validation
study was to observe that whereas the microarray analy-
sis showed no specific methylation profile for HER2-
overexpressing tumors (luminal B and ERBB2+ tumors),
the validation study (carried out in a larger sample size)
demonstrated that HER2-overexpressing tumors had a
common methylation profile.
The analysis of DNA-methylation profiles with regard
to the tumors’ clinicopathologic features revealed that
hypermethylation of HS3ST2 was more prevalent in
patients with nodal involvement (c
2 =1 0 . 6 1 ;P <0 . 0 0 1 ) ,
whereas RASSF1 hypermethylation was associated with
the presence of p53 mutations (c
2 =7 . 5 1 ;P <0 . 0 0 1 )
and high Ki-67 index (c
2 = 15.63; P < 0.001). In addi-
tion, promoter hypermethylation of TAL1 and SPARC
genes was more frequent in tumors with high histologic
grade (c
2 = 6.41 and c
2 = 6.21, respectively; P < 0.05).
We next combined all the methylation data into a sin-
gle variable, the mean Z score, to allow further analysis.
As shown in Figure 2c, mean methylation density in
tumors was significantly higher than that in adjacent tis-
sue [-1.26 (CI, -1.26 to -1.17) and -0.01 (CI, -0.81 to
0.72); P < 0.001]. Additionally, we found significant dif-
ferences in the mean Z scores among the different breast
cancer subtypes [basal-like, -0.45 (-0.58 to -0.32); luminal
B ,0 . 2 4( 0 . 0 9t o0 . 3 9 ) ;E R B B 2 + ,0 . 2 2( 0 . 0 5t o0 . 4 1 ) ;a n d
luminal A, -0.02 (-0.14 to 0.09); P < 0.001] (Figure 3c),
and that significantly higher Z-score epigenotypes were
related to LINE-1 hypomethylated tumors [0.27 (CI, 0.04
to 0.28) and -0.06 (CI, -0.13 to 0.02; P < 0.05], HER2-
overexpressing breast cancers [0.25 (CI, 0.15 to 0.37) and
-0.22 (CI, -0.33 to -0.22); P < 0.001], and node-positive
tumors [0.11 (CI, -0.01 to 0.19) and -0.10 (CI, -0.25 to
0.4); P < 0.05], which are features associated with clini-
cally more-aggressive tumors. Paradoxically, highly pro-
liferative and p53-mutated tumors, both associated with
the basal-like phenotype, showed significantly lower Z
scores of methylation [-0.17 (CI, -0.35 to 0.01) and 0.11
(CI, -0.03 to 0.26); P < 0.001] and [-0.23 (CI, -0.44 to
-0.11) and 0.12 (CI, -0.02 to 0.26); P < 0.001] respectively.
Table 1 Patient characteristics of both marker discovery and validation studies
Type
Basal ERBB2+ Luminal B Luminal A
Number of patients 59 49 54 53
Age (years)
Mean 56.1 57.1 56.9 62.9
Median 53 57.5 51 61
Range (95% CI) 51.5-60.7 52.5-61.6 51.8-61.7 56.9-68.7
Tumor size (cm)
Mean 2.4 2.8 3.2 3.1
Range (95% CI) 2.1-2.7 2.1-3.5 2.5-3.5 2.4-3.7
Histologic grade (%)
I 5.0 0.0 0.0 6.0
II 47.1 24 40.0 55.5
III 48.9 76 60.0 38.5
Nodal involvement (%)
Positive 35.5 63.4 72.2 57.3
Negative 64.4 36.6 27.8 42.7
Ki-67 overexpression (%)
<10% 0.0 8.9 21.9 27.8
10%-25% 0.0 36.1 31.2 66.7
>25% 100.0 56.0 46.9 5.6
p53 mutation (%)
Positive 47.2 44.1 21.8 14.8
Negative 52.8 55.9 88.2 85.2
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Page 5 of 12Figure 1 Supervised hierarchic clustering of 28 paired breast cancer samples by using methylation microarray data from differentially
methylated genes. Heat map and clustering of 76 significant (FRD-corrected, P < 0.001) differences between tumors (red) compared with
adjacent tissues (green) shows that 30 of the differences (corresponding to 25 genes) are increases of methylation, whereas 47 (corresponding
to 37 genes) are decreases of promoter methylation in tumors. Heat-map colors symbolize DNA methylation, as indicated in the color key. The
full list of genes is presented in Table S2 in Additional file 2.
Bediaga et al. Breast Cancer Research 2010, 12:R77
http://breast-cancer-research.com/content/12/5/R77
Page 6 of 12Novel DNA methylation profiles with subtype-predictive
value
Selected loci were further processed to identify the
best biomarker panel allowing classification in tumor
subtypes. Multivariate logistic regression (MLR) analy-
sis was performed to identify potential biomarker
panels with the best sensitivity, specificity, and false
discovery rate (FDR). We first pruned all the variables
showing significance in univariate analysis (Table 3) by
using all-subset selection with Mallows’ Cp optimiza-
tion criteria, and recognized biomarker panels capable
of discriminating basal-like and HER2-overexpressing
subtypes at FDR 0.2 level. Specifically, basal-like
tumors were inversely associated with hypermethyla-
tion of NPY, FGF2, HS3ST2, RASSF1,a n dLet-7a mar-
kers (sensitivity, 75%; specificity, 95%; and FDR, 0.17),
whereas HER2-overexpressing subtypes were strongly
correlated to hypermethylation of NPY, FGF2, HS3ST2,
RASSF1,a n dLet-7a (sensitivity, 74%; specificity, 80%,
and FDR, 0.18).
The supervised hierarchic-clustering analysis based on
these five genes resulted in three different clusters of
tumor groups (C1 to C3) (Figure 3). Samples fitting in
cluster C1 (characterized by lack of methylation) were
mostly basal-like tumors; cluster C2 was the most het-
erogeneous one with regard to both methylation status
of the genes and samples fitting into it. This cluster
contains the majority of the luminal A samples, but also
includes some luminal B and ERBB2+ tumors. Conver-
sely, cluster C3 (hypermethylated in almost all the ana-
lyzed markers) was basically composed of luminal B and
ERBB2+ samples (HER2-overexpressing subtypes).
Discussion
Identification of gene expression-based breast cancer
subtypes is considered a critical means of prognostica-
tion, and furthermore, an important predictive marker
for the response to treatment with endocrine therapy.
However, analytic tests relying on RNA measures are
difficult to standardize and implement because of the
instability of the mRNA transcripts. DNA-methylation
profiles reflect phenotypically important differences in
gene transcription and, in contrast to most mRNAs, a
very stable structure, making DNA-methylation profile-
based diagnostic tests highly accurate and reproducible
[31]. By use of two independent cohorts of invasive
Figure 2 Supervised hierarchic clustering of 187 paired breast cancer samples by using methylation data from selected genes in the
validation study. (a) Heat map and clustering of significant (FRD-corrected, P < 0.01) differences between tumors (red) and adjacent tissues
(green). Heat-map colors symbolize DNA methylation, as indicated in the color key. (b) Principal component analysis (PCA) plots showing
separation between tumor and adjacent tissue. (c) Box plots showing lower methylation density in adjacent tissue compared with tumors.
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Gene Methylation level (mean ± SD) (positive rate
a)
Basal like Luminal B ERBB2+ Luminal A P value
b
CD40 24.3 ± 12.3 (21.7) 30.8 ± 11.9 (36.2) 30.8 ± 11.9 (33.4) 27.4 ± 7.9 (23.9) <0.001
DBC1 12.8 ± 9.2 (15.9) 19.9 ± 10.3 (34.1) 17.8 ± 8.2 (42.7) 14.0 ± 7.3 (19.5) <0.001
FGF2 7.4 ± 7.2 (11.1) 23.1 ± 11.2 (63.8) 32.2 ± 13.9 (67.5) 15.0 ± 13.4 (30.8) <0.001
HOXA9 21.1 ± 12.0 (61.8) 22.5 ± 9.4 (64.7) 28.4 ± 10.3 (83.8) 20.3 ± 8.0 (78.1) NS
HS3ST2 10.3 ± 11.9 (31.0) 23.9 ± 12.9 (75.0) 26.8 ± 12.3 (79.8) 17.5 ± 13.2 (40.4) <0.001
JAK 3 28.0 ± 15.3 (53.5) 36.8 ± 15.2 (87.5) 33.3 ± 13.7 (74.1) 28.8 ± 10.3 (83.0) <0.001
Let-7a 33.9 ± 11.3 (19.1) 55.1 ± 10.9 (72.9) 48.8 ± 15.7 (65.7) 53.5 ± 8.4 (80.0) <0.001
LINE-1 63.8 ± 3.2 (30.2) 63.1 ± 6.2 (40.4) 63.8 ± 7.8 (40.2) 62.8 ± 4.7 (30.4) NS
Mir-10a 15.5 ± 4.2 (36.4) 25.2 ± 5.8 (70.8) 23.1 ± 10.1 (77.4) 20.8 ± 11.3 (63.2) <0.001
Mir-93 a 55.6 ± 7.3 (23.9) 60.6 ± 6.5 (57.8) 61.2 ± 8.9 (62.1) 61.3 ± 6.5 (47.5) <0.001
NPY 14.9 ± 4.9 (35.6) 38.9 ± 14.6 (95.8) 34.5 ± 14.5 (80.9) 27.4 ± 14.8 (78.6) <0.001
PRKCDBP 7.6 ± 6.1 (4.3) 13.2 ± 10.0 (12.5) 15.6 ± 10.1 (22.3) 10.6 ± 8.4 (15.0) <0.001
RASSF1 20.4 ± 11.9 (35.7) 33.9 ± 12.9 (79.2) 35.6 ± 10.8 (74.5) 23.5 ± 5.9 (73.9) <0.001
SOX 1 19.8 ± 10.7 (75.0) 24.5 ± 11.2 (81.3) 21.5 ± 10.1 (78.6) 20.7 ± 10.1 (53.3) <0.001
SOX17 19.1 ± 15.6 (59.1) 22.4 ± 14.2 (70.8) 23.2 ± 14.7 (62.4) 14.1 ± 7.2 (32.4) <0.001
SPARC 35.3 ± 10.7 (48.9) 33.7 ± 10.2 (60.4) 34.5 ± 12.2 (67.3) 31.1 ± 11.0 (68.1) NS
TAL1 38.8 ± 12.5 (59.1) 33.9 ± 11.3 (56.5) 37.7 ± 11.6 (60.4) 27.4 ± 7.9 (52.3) NS
TNFRS10D 12.5 ± 12.6 (27.8) 18.9 ± 8.8 (60.9) 23.5 ± 11.3 (65.7) 19.6 ± 9.2 (60.0) <0.001
VAMP8 8.8 ± 3.8 (93.1) 12.4 ± 4.4 (72.1) 11.4 ± 3.9 (77.2) 11.9 ± 4.1 (79.2) <0.001
aPositive rate using the sample mean plus 2 times the SD of the pooled normal samples (and minimum 10% methylation) as a cut-off point.
bP value computed
by using the ANOVA or Kruskal-Wallis tests, as appropriate.
Figure 3 Supervised hierarchic clustering of the five candidate genes (Let-7a, NPY, RASFF1, FGF2,a n dHS3ST2). Differential methylation
of patterns is shown by red (hypermethylated) versus green (nonmethylated) colors. As noted, three differentiated clusters (C1 to C3) are
generated by this statistical analysis. Underneath, box plots showing differential methylation density among tumor subtypes.
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Page 8 of 12breast carcinomas, our study is, to our knowledge, one
of the first to deliver specific methylation profiles asso-
ciated with basal-like, ERBB2+, luminal A, and luminal
B molecular subtypes of breast cancer.
Statistical analysis of the methylation microarray data
revealed extensive DNA-methylation changes between
tumor and adjacent tissue (Figure 1, Table S2 in
Additional file 2) and concurrence of some of these
DNA-methylation changes with particular breast cancer
molecular subtypes and tumor morphologies. Applying
stringent criteria, we identified significant differential
methylation among the tumor subtypes in 15 of the
1,505 screened CpG islands. Subsequent validation of
the selected genes plus four more from the literature by
pyrosequencing in an independent cohort of 187 breast
tumor/normal pairs, confirmed that genes tested have
significantly altered methylation profiles in comparison
to normal-appearing adjacent tissue, and that most of
the candidate genes (15 of 19) displayed significantly dif-
ferent methylation profiles between different tumor sub-
types. These results corroborate the potential usefulness
of the studied markers for the development of a methy-
lation marker panel defining tumor subtypes. Moreover,
the current study represents the first evidence for DNA
hypermethylation of N P Y ,F G F 2 ,C D 4 0 ,T A L 1 ,J A K 3 ,
SPARC, PRKCDBP, DBC1, SOX1, TNFRS10D, Let-7a,
Mir-10a, and Mir-93 and hypomethylation of VAMP8 in
breast cancer.
Several genes have been previously reported to be
aberrantly methylated in breast cancer (reviewed in
[32-34]). Furthermore, methylation in breast cancer has
already been connected to breast cancer molecular sub-
types, but these observations require further confirma-
tion. As previously suggested, we found that basal-like,
ERBB2+, luminal A, and luminal B molecular subtypes
displayed specific methylation profiles. Specifically,
H E R 2 - e n r i c h e db r e a s tt u m o r s( E R B B 2 +a n dl u m i n a lB )
were associated with the hypermethylation of several
genes related to cancer development (Table 3). These
results are in accordance with previous studies stating
that HER2/neu breast cancers are associated with pre-
ferential hypermethylation of several genes [21-23]. In
addition, Terada et al. [35] recently found that frequent
CpG islands methylation is highly associated with HER2
amplification. Conversely, we observed that basal-like
tumors were inversely related to promoter methylation
of many of the studied genes (Table 3) and showed the
lowest methylation levels among the studied subtypes,
as indicated by the mean Z-score values (Figure 3c).
These findings are consistent with the recent observa-
t i o n sm a d eb yH o l met al. [36], who reported that
basal-like tumors have low methylation levels of several
CpG sites, whereas luminal B tumors display high
methylation levels.
Additionally, our efforts to identify and validate breast
cancer subtype-specific epigenotypes resulted in a signif-
icant model based on five biomarkers, which is capable
of discriminating basal-like and HER2-overexpressing
subtypes. Basal-like tumors showed lack of methylation
at NPY, FGF2, HS3ST2, RASSF1,a n dLet-7a markers,
whereas HER2-overexpressing tumors (luminal B and
ERBB2+ subtypes) were related to hypermethylation of
these markers.
Several authors have speculated that these genomically
defined tumor subtypes may represent transformation of
stem cells. Some of these hypotheses suggest that mam-
mary stem cells progress to a luminal progenitor state
(with an expression pattern similar to that identified in
basal breast cancer), which then progresses to differen-
tiated cells with more luminal characteristics [37]. As
can be deduced, this hypothesis locates basal-like
tumors in an intermediate differentiation step between
the mammary stem cells and the more-differentiated
luminal subtypes, which would explain their poor prog-
nosis despite response to chemotherapy [38]. Many stu-
dies have been conducted to define methylation profiles
in human stem cells [39-42]. Likewise, Calvanesse et al.
[43] compared the methylation status in human
embryonic stem cells (hESCs), cancer cell lines, and nor-
mal human primary tissues by using the same platform
as that in our study. Their finding was consistent with
the view that genes aberrantly hypermethylated in can-
cer (that is, not hypermethylated in normal tissues) were
not hypermethylated in hESCs, termed by these authors
the classic class A cancer hypermethylated genes. Inter-
estingly, all the CpG sites related to basal-like tumors in
univariate regression analysis, with the exception of
RASSF1 (Table 3), belonged to this committed class A
category, and in a manner analogous to hESCs; they
were not hypermethylated in basal-like tumors, nor in
normal breast, but they were hypermethylated in the
rest of breast cancer subtypes, suggesting that basal-like
Table 3 Subtype-specific methylation profiles in univariate analysis
Tumor subtype Related genes
a
Basal-like JAK3(-), NPY(-), RASSF1(-), SPARC(-), DBC1(-), FGF2(-), HS3ST2(-), PRKCDBP(-), TNFRS10D(-), and VAMP8(+)
HER2 overexpressing NPY(+), DBC1(+), FGF2(+), RASSF1(+), HS3ST2(+), SOX17(+), and TNFRS10D(+)
Luminal A SOX1(-), SOX17(-), and VAMP8(+)
aRelated genes in univariate logistic regression analysis at 0.05 significance level. (+), positively, and (-) negatively related.
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Page 9 of 12tumors may share some similarities in their methylation
patterns with those of the hESC cell lines. These shared
methylation signatures may reinforce the hypothesis of
basal-like tumors arising from a mammary stem cell and
progressing to differentiated cells with more luminal
characteristics (HER2 enriched, luminal A and B).
A recent study by Holm et al. [36] also supported this
hypothesis; they observed that basal-like tumors seem to
arise from luminal progenitors in which genes initiating
a differentiated luminal cell fate are repressed by other
mechanisms than promoter methylation, such as the
Polycomb repressive complex 2 (PRC2).
Finally, epigenetic therapy, including the use of
demethylating agents and histone deacetylase inhibi-
tors, is now in clinical trials for myelodysplastic syn-
drome, leukemia, and ovarian and lung cancers [21].
Recent studies have suggested that co-treatment of
DNA-methylation inhibitors and histone deceatylases
m i g h tb ea ne f f e c t i v ef o r mo fe p i g e n e t i ct h e r a p yf o r
breast cancer, as the interplay observed between DNA
methylation and histone modifications can result in
synergistic induction of tumor-suppressor genes
[21,44]. Thus, a possibility exists that epigenetic ther-
apy could play an important role in the immediate
future of breast cancer treatment. The information on
subtype-specific methylation profiles, described in the
present study, might promote a better understanding
of the epigenetic regulation mechanisms in breast can-
cer, thereby contributing to the improvement of epige-
netic therapy.
Conclusions
In this study, we used a microarray approach followed
by substantial technical and biologic validation to iden-
tify specific epigenotypes for particular subtypes in
breast cancer. We clearly demonstrate the differences in
the methylation profiles of basal-like and HER2-overex-
pressing tumors and provide evidence to support the
utilization of this biomarker for prognostication and
therapeutic stratification of patients with breast cancer.
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